免疫球蛋白游离轻链的检测与临床应用

doi:10.16150/j.1671-2870.2017.05.004

摘要/Abstract

中图分类号:

R551.3

彭奕冰, 章黎华. 免疫球蛋白游离轻链的检测与临床应用[J]. 诊断学理论与实践, 2017, 16(05): 468-471.

[1] Dispenzieri A, Kyle R, Merlini G, et al.International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders[J]. Leukemia,2009,23(2):215-224.
[2] Dejoie T, Corre J, Caillon H, et al.Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma[J]. Blood,2016, 128(25):2941-2948.
[3] Katzmann JA, Kyle RA, Benson J, et al.Screening pane-ls for detection of monoclonal gammopathies[J]. Clin Chem,2009,55(8):1517-1522.
[4] Holding S, Spradbery D, Hoole R, et al.Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies[J]. Clin Chem Lab Med,2011,49(1):83-88.
[5] 王继贵. 用血清游离轻链分析法检测单克隆γ-病[J]. 实验与检验医学,2014,32(3):233-236.
[6] Abadie JM, Bankson DD.Assessment of serum free light chain assays for plasma cell disorder screening in a Vete-rans Affairs population[J]. Ann Clin Lab Sci,2006,36(2):157-162.
[7] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:30-31.
[8] Matters DJ, Solanki M, Jones R, et al.Statistical analysis of free light chain results between seven nephelometric and turbidimetric platforms[J]. Clin Chem,2008,54:C107a.
[9] Rajkumar SV, Landgren O, Mateos MV.Smoldering multiple myeloma[J]. Blood,2015,125(20):3069-3075.
[10] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:233-234.
[11] Mead GP, Carr-Smith HD, Drayson MT, et al.Serum free light chains for monitoring multiple myeloma[J]. Br J Haematol,2004,126(3):348-354.
[12] Bradwell AR.Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:130-153.
[13] Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, et al.Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma[J]. Br J Haematol,2007,137(3):240-243.
[14] Snozek CL, Katzmann JA, Kyle RA, et al.Prognostic va-lue of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system[J]. Leukemia,2008,22(10):1933-1937.
[15] Dispenzieri A, Lacy MQ, Katzmann JA, et al.Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation[J]. Blood,2006, 107(8):3378-3383.
[16] Rajkumar SV, Kyle RA, Therneau TM, et al.Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance[J]. Blood,2005,106(3):812-817.
[17] Alhaj Moustafa M, Rajkumar SV, Dispenzieri A, et al.Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy[J]. Leukemia,2015,29(10):2033-2038.
[18] Larsen JT, Kumar SK, Dispenzieri A, et al.Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma[J]. Leukemia,2013,27(4):941-946.
[19] Tacchetti P, Cavo M, Rocchi S, et al.Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens[J]. Leuk Lymphoma,2016,57(9):2058-2064.
[20] Hassoun H, Reich L, Klimek VM, et al.The serum free light chain ratio after one or two cycles of treatment is highly predictive of the magnitude of final response in patients undergoing initial treatment for Multiple Myeloma[J]. Blood,2005,106:972a.
[21] Durie BG, Harousseau JL, Miguel JS, et al.International uniform response criteria for multiple myeloma[J]. Leukemia,2006,20(9):1467-1473.
[22] Kyle RA, Rajkumar SV.Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma[J]. Leukemia,2009,23(1):3-9.
[23] Bradwell AR. Serum free light chain analysis[M]. 6th. Birmingham, UK: The Binding Site Group Ltd,2010:61-76,138-142.

免疫球蛋白游离轻链的检测与临床应用

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	游利. 重视骨转换指标的临床应用及评估[J]. 诊断学理论与实践, 2020, 19(03): 214-218.
[2]	陈辰, 张月, 胡晓波. 尿路感染报警信息阈值设置和临床应用评价[J]. 诊断学理论与实践, 2020, 19(02): 168-171.
[3]	余红, 王一飞, 陈佳, 陈洁, 李斌. 青蒿素及其衍生物在皮肤疾病中的作用机制研究及临床应用[J]. 诊断学理论与实践, 2019, 18(2): 233-236.
[4]	上海市医学会分子诊断专科分会, 上海市临床检验中心, 上海东方肝胆外科医院, 中华医学会检验医学分会临床免疫学组, 中国中西医结合检验学会肝病学术委员会, 全军肝胆外科专业委员会, 上海免疫学会肿瘤免疫分会, 上海抗癌协会肿瘤标志物分会. 多学科甲胎蛋白异质体临床应用专家共识[J]. 诊断学理论与实践, 2018, 17(01): 19-24.
[5]	朱巍巍, 万颖蕾, 刘锦燕, 张华, 陈华, 项明洁. 内毒素的检测方法与临床应用进展[J]. 诊断学理论与实践, 2017, 16(06): 668-671.
[6]	汪萍, 沈立松, 张冬青. 多发性骨髓瘤及相关疾病的实验室诊断认识[J]. 诊断学理论与实践, 2017, 16(05): 477-483.
[7]	陈颖, 李翠, 应春妹. 复发性自然流产患者T细胞中T细胞免疫球蛋白和免疫受体酪氨酸抑制基序的表达[J]. 诊断学理论与实践, 2017, 16(03): 273-276.
[8]	沈立松, 马妍慧,. 质谱技术在检验医学中的应用现状和前景[J]. 诊断学理论与实践, 2012, 11(05): 536-538.
[9]	张郁苒, 于青, 姚建,. 血清IgA及IgA/C3比值在IgA肾病诊断中的价值[J]. 诊断学理论与实践, 2009, 8(02): 191-193.
[10]	张伟滨, 吴春阳, 杨珏琴, 姚芳娟, 范丽安,. 中国汉族人群骨肿瘤杀伤细胞免疫球蛋白样受体基因多态性初步分析[J]. 诊断学理论与实践, 2006, 5(05): 420-424.
[11]	沈璟璟, 钟璐, 王海嵘, 钟济华, 陈芳源, 欧阳仁荣,. 免疫球蛋白重链和T细胞受体基因重排与急性髄细胞白血病的关系[J]. 诊断学理论与实践, 2006, 5(05): 401-403.
[12]	朱承谟. 积极开展PET、SPECT显像的临床应用和研究[J]. 诊断学理论与实践, 2005, 4(02): 89-90.
[13]	李彪,朱承谟. 正电子放射性药物的临床应用与进展[J]. 诊断学理论与实践, 2005, 4(02): 93-95.
[14]	冷海燕,朱萍,丁天凌,谢毅. 流式细胞术检测红细胞相关抗体方法[J]. 诊断学理论与实践, 2005, 4(01): 65-67.
[15]	王鸿利. 血液学实验诊断的现状特点与应用价值[J]. 诊断学理论与实践, 2004, 3(06): 5-7.